RxDoctor Payments Data

Moe Zaw, MD

Pulmonary Disease · Miami, FLNPI 1063751444

Payments from drug & device makers

$807in general payments, 2019–2025

Across 16 payments — averaging $50.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$225
  • AstraZeneca$125
  • Mallinckrodt Enterprises LLC$123
  • Jazz Pharmaceuticals Inc.$107
  • Itamar Medical Inc$103
  • Insmed, Inc.$34
  • plus $90 from 4 others

What the payments were for

  • Food & beverage$79098%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$807 in reported general payments places this provider in the 25th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$28,735
Medicare patients
107
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate23$293,677
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$117,080
Breo ElliptaFluticasone/Vilanterol35$16,563
Spiriva RespimatTiotropium Bromide13$12,066
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,811
SymbicortBudesonide/Formoterol Fumarate28$8,571
Advair HfaFluticasone Propion/Salmeterol21$7,804
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,009
Albuterol Sulfate HfaAlbuterol Sulfate88$2,006
Azelastine Hcl47$1,172
Fluticasone Propionate39$564
Omeprazole15$338
Azithromycin14$245
Montelukast Sodium12$148
Prednisone23$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$30$305,74336 claims
GSKTrelegy Ellipta, Breo Ellipta$24$133,643180 claims
AstraZenecaBreztri Aerosphere, Symbicort$125$20,38239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →